UAS
AKTX

United Asset Strategies’s Akari Therapeutics AKTX Stock Holding History

United Asset Strategies’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-362
Closed -$765K – 208
2021
Q1 		$765K Buy
362
+4
+1% +$9.07K 0.11% 131
2020
Q4 		$530K Hold
358
– – 0.08% 141
2020
Q3 		$499K Sell
358
-17
-5% -$25.2K 0.09% 139
2020
Q2 		$654K Buy
+375
New +$571K 0.13% 112

Other funds holding AKTX

OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

United Asset Strategies's AKTX Position: Q2 2021 in Review

United Asset Strategies sold out of Akari Therapeutics (AKTX) in Q2 2021, closing a stake of 362 shares — an estimated $765K sold.

United Asset Strategies first reported a position in AKTX in Q2 2020 and held it in 4 quarters. The position peaked at $765K in Q1 2021. 12 funds tracked by Wall St. Rank hold AKTX as of Q2 2021.

  • United Asset Strategies reported no remaining Akari Therapeutics position as of Q2 2021 after selling out during the quarter.
  • United Asset Strategies sold 362 Akari Therapeutics shares in Q2 2021, an estimated $765K.
  • United Asset Strategies first reported a position in Akari Therapeutics in Q2 2020 and held it in 4 quarters.
  • United Asset Strategies's Akari Therapeutics position peaked at $765K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2021.

Based on United Asset Strategies's 13F filing for Q2 2021, filed 19 Jul 2021.